When a healthy preterm baby catches RSV, it can quickly turn into a stressful trip to the doctor. A fresh look at older research suggests a preventive shot called palivizumab could be a strong shield. The analysis pooled data from three studies involving over 2,400 healthy infants born at 35 weeks or earlier. It found that for babies born between 29 and 35 weeks, palivizumab reduced these medically attended RSV infections by about 70% compared to a placebo shot. The researchers also noted its performance looked broadly similar to a newer drug, nirsevimab. But here's the catch: the researchers themselves flag that there's limited data on how well palivizumab prevents these specific outpatient infections. We're only seeing a percentage reduction, not the actual number of babies it helped. The report doesn't include any information on side effects or safety, which is a crucial piece of the puzzle for parents and doctors. This isn't a new clinical trial, but a re-analysis of existing studies, which means we're working with what was collected years ago. The finding is a useful data point, but it comes with significant unknowns that need to be filled in.
Palivizumab reduces medically attended RSV infections in preterm infants, shows similar efficacy to nirsevimabCan an older RSV drug protect healthy preterm babies from doctor visits?
AI-generated summary of the cited source, checked by automated accuracy review. How we work
This meta-analysis pooled data from three randomized, placebo-controlled studies involving 2,464 healthy infants born at ≤35 weeks' gestational age. It evaluated palivizumab versus placebo for preventing medically attended, non-hospitalized respiratory syncytial virus infections (MARI) and RSV-related hospitalization. The setting and follow-up duration were not reported.
For the primary outcome of MARI in infants born at 29-35 weeks' gestational age, palivizumab showed a 70.5% reduction compared with placebo. The analysis also indicated that palivizumab had broadly similar efficacy to nirsevimab for preventing MARI. However, the researchers reported no absolute numbers, p-values, or confidence intervals for these efficacy estimates. RSV-related hospitalization was a secondary outcome, but specific results were not provided in the available data.
No safety, tolerability, or adverse event data were reported for palivizumab in this analysis. Key limitations include limited data specifically on palivizumab efficacy at preventing MARI and the absence of absolute effect sizes, confidence intervals, and direct comparative statistical analysis with nirsevimab (only described as 'broadly similar').
For practice, this meta-analysis suggests palivizumab may reduce medically attended RSV infections in preterm infants, with efficacy appearing comparable to nirsevimab based on limited comparative assessment. However, clinicians should note the evidence comes from a meta-analysis with significant data gaps—particularly regarding absolute risk reduction, precision of estimates, and safety information—which limits definitive conclusions about comparative effectiveness.
More on Respiratory Syncytial Virus Infection
View Original Abstract ↓
High-Dose Vitamin D and Low-Dose Vitamin A May Reduce Bronchopulmonary Dysplasia in Preterm Infants
High-Dose Vitamin D May Reduce BPD in Preterm Infants
Related in Pediatrics
From Other Specialties
